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The mitochondria are dynamic organelles that constantly fuse and divide. An equilibrium between fusion and fission controls the morphology
of the mitochondria, which appear as dots or elongated tubules depending the prevailing force. Characterization of the components of the fission
and fusion machineries has progressed considerably, and the emerging question now is what role mitochondrial dynamics play in mitochondrial
and cellular functions. Its importance has been highlighted by the discovery that two human diseases are caused by mutations in the two
mitochondrial pro-fusion genes, MFN2 and OPA1. This review will focus on data concerning the function of OPA1, mutations in which cause
optic atrophy, with respect to the underlying pathophysiological processes.
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Cellular proliferation requires the biogenesis and transmis-
sion of the intracellular organelles. Biogenesis of the mito-Abbreviations: mtDNA, mitochondrial DNA; GED, GTPase effector
domain; MIS, mitochondrial import sequence; HS, hydrophobic segment;
MPP, Mitochondrial processing peptidase; IMS, inter membrane space; IM,
inner membrane; OM, outer membrane; PEG, polyethylene glycol; mito-PAGF,
mitochondrial matrix targeted photoactivable Green Fluorescent Protein;
ADOA, autosomal dominant optic atrophy; LHON, Leber hereditary optic
neuropathy; ORF, open reading frame; RGC, retinal ganglion cells; MELAS,
mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like
episodes; LS, Leigh syndrome; KSS, Kearns–Sayre syndrome; NARP,
neuropathy, ataxia, and retinitis pigmentosa; MERRF, myoclonic epilepsy
associated with ragged-red fibers
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doi:10.1016/j.bbamcr.2006.04.003chondria, the major and essential role of which is to provide
cellular energy by oxidative phosphorylation, results from the
growth and division of pre-existing organelles [1]. Since the
mitochondrial DNA (mtDNA) specifies only the mitochondrial
translation machinery, and a limited number of proteins
implicated in the respiratory chain, the nuclear genome makes
an essential contribution to the biogenesis, transmission and
function of the mitochondria.
The metabolic functions of the mitochondria have been
studied for many years, but it is only recently that the mor-
phology of the mitochondrial network, in relation with the
functioning and transmission of this organelle, has been started
to be reconsidered. Major advances in this domain have been
made possible by the isolation of yeast mutant strains deficient
for the transmission, maintenance and organization of the mito-
chondria. Their characterization has led to the proposal that the
morphology of the mitochondrial network depends on the
equilibrium between two antagonistic forces acting on the
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Fig. 1. Schematic representation of the domain structure of OPA1. OPA1 shares
a number of structural features with proteins of the dynamin family. These
include a GTPase domain containing the three consensus GTP binding
sequences (red bars) and the dynamin signature (red hatched bar), a middle
domain and a C-terminal coiled-coil region which may correspond to a GTPase
effector domain (GED). Only dynamin itself contains a pleckstrin homology
domain (PH) that binds lipids, while the association of OPA1 with mitochondrial
membranes could be related to the presence of two hydrophobic segments (HS)
located immediately after the N-terminal mitochondrial import sequence (MIS).
The C-terminal regulator prolin rich domain (PRD) is also found only in the
conventional dynamins. In OPA1, a N-terminal coiled-coil region (CC) is
located immediately before the GTPase domain. Yeast orthologues of OPA1,
Mgm1p and Msp1p, display the same structural organization.
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For example, the state of the mitochondrial outer membrane
is determined by both fission, driven by the dynamin Dnm1p,
and fusion, controlled by the GTPase Fzo1p. The description
of other elements of the outer membrane involved in the
control of mitochondrial dynamics has recently been refined
by the identification of genetic and biochemical partners of
Dnm1p and Fzo1p. Most of these proteins are conserved in
higher eukaryotes where they fulfill similar functions (Table
1). The dynamics of the inner membrane, and the mechan-
isms involved in the modeling of the cristae, which are now
considered to be dynamic tubular projections of the inner
membrane [2], are not well characterized. OPA1, and its
yeast counterparts, Mgm1p and Msp1p, are believed to control
these processes. Furthermore, recent studies have implicated
Mitofilin [3] and ATP synthase [4] as critical organizers of
the cristae morphology (Table 1).
Numerous reviews addressing the critical role of mito-
chondrial dynamics in determining mitochondrial morphology
are available (see the reviews listed in [5] and the related
issues in this volume), while its requirement in the function
of the mitochondria and at the cellular level is considerably
less well characterized [6]. However, the importance of
mitochondrial dynamics has been highlighted recently by the
discovery that two inherited human diseases are caused by
mutations in two mitochondrial fusion genes [7–9]. This
review will focus on data concerning the function of one of
these genes, OPA1.2. From yeast to ADOA
2.1. Mgm1p/Msp1p/OPA1, a conserved mitochondrial dynamin
Mgm1+ was first identified in a genetic screen for nuclear
genes required for the maintenance of mtDNA in the budding
yeast S. cerevisiae [10]. We then isolated its orthologues,Msp1+
in the fission yeast S. pombe [11] and OPA1 in humans [7], and
showed that the function of this gene has been conserved during
evolution since expression of OPA1 can complement the loss of
msp1+ in S. pombe [12].
Mgm1p, Msp1p and OPA1 are members of the dynamin
family [7,10,11,13–16]. They consist of an N-terminal mito-
chondrial import sequence (MIS), followed by short hydropho-
bic stretches, a coiled-coiled domain, a GTPase domain, a
middle domain, and a C-terminal coiled-coil domain known as
the GTPase Effector Domain (GED) (Fig. 1). The MIS targets
the protein to the mitochondria and is cleaved by the
mitochondrial processing peptidase (MPP) upon import [17–
21]. While the sub-mitochondrial localization of this dynamin
has long been the subject of controversy, it is now accepted that
all three homologues are localized to the inter-membrane space
(IMS) [17,19,22–26]. Nevertheless, some discrepancies still
persist concerning the relationship of these dynamins with the
mitochondrial membranes. Mgm1p has been shown to be either
peripherally associated with, or integrated into, the inner or outer
membranes (IM or OM respectively) [17,22,24,27], while
Msp1p is anchored in the IM [18]. OPA1 has been shown to
co-sediment with both mitochondrial membranes and to interact
more or less tightly with the IM [19,21,26]. Further studies are
needed to clarify this point, keeping in mind that the existence of
several forms of these dynamins could explain these controver-
sial findings [19,21,22,27,28]. In particular, a short form of
Mgm1p, carrying a deletion in the N-terminal region, is
generated by the action of the mitochondrial rhomboid-type
protease Pcp1p [17,29,30]. While generation of the long MMP-
matured and the short rhomboid-matured forms of this dynamin
seems to be a feature that is conserved in both budding and
fission yeasts (our unpublished data), and although the
mammalian PARL can replace its yeast Pcp1p counterpart
[29], it is not clear if OPA1 is similarly processed by a rhomboid
Fig. 2. Possible roles for OPA1. OPA1 (in pink) anchored to the inner
membrane (IM) could controls its dynamic in coordination with the dynamic
outer membrane (OM) by interacting either directly or indirectly with Mfn2
(in grey). Oligomerized OPA1 could structure the cristae or could control the
cristae junction opening, sequestering cytochrome c (in green) in intra-cristae
compartment.
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may originate from the 8 alternatively spliced mRNA variants
[28] and/or proteolytic or yet unknown post-translational
modifications.
Loss of Mgm1p, Msp1p or OPA1 by either gene deletion or
RNAi experiments in yeast and mammalian cells respectively
leads to fragmentation of the mitochondrial tubules
[22,25,26,31]. This could be due to an increased rate of
mitochondrial division or a decrease in the capacity of the
mitochondria to fuse. The later hypothesis was indeed first
evidenced in S. cerevisiae zygotes formed by mating MGM1
null mutants which are unable to mix their mitochondrial
contents [23,24], and then in OPA1-depleted mammalian cells
by PEG [32] or mito-PAGF [33] fusion assays [34,35].
Accordingly, while abolishing the function of the dynamin
Dnm1p, the major actor of mitochondrial fission in S. cerevisiae,
blocks mitochondrial fragmentation resulting from the loss of
Mgm1p it does not restore the fusion-induced defect [23,24].
OPA1 may work together with the mitofusins (Mfn), large
GTPases involved in OM fusion [36–39], to promote mito-
chondrial fusion. Consistent with this idea, OPA1 was shown to
require Mfn1 (and not Mfn2) to induce mitochondrial tubulation
[34]. Furthermore, biochemical interactions involving the pro-
fusion Ugo1p were reported to occur between Mgm1p and
Fzo1p (the Mfn orthologue) [23,30,40] in S. cerevisiae.
However, this has yet to be demonstrated in mammalian cells
that presumably lack an UGO1 homologue. This interaction
may serve to physically coordinate the dynamics of IM and OM.
Surprisingly, while OPA1 and its yeast counterparts are
believed to promote fusion of mitochondrial membranes, over-
expression of the dynamin in HeLa and Cos-7 cells causes
mitochondrial fragmentation [20,26] (our unpublished data).
This paradox may be explained by a non-specific effect due to
over-expression of a membrane protein in the tubular
mitochondrial network. However, recent data showing that
MEFs overexpressing OPA1 fused their mitochondria as
efficiently as untransfected cells indicates that the mitochondrial
fragmentation seen in these cells is not due to lack of fusion
[41]. Furthermore, over-expression of OPA1 promoted mito-
chondrial elongation in cells in which the mitochondria are
naturally fragmented [19, 34]. Taken together, these observa-
tions may point to the existence of surveillance mechanisms
which, while allowing local membrane dynamics, maintain the
mitochondrial network within a morphological state compatible
with its function in a given cell type. Thus in HeLa and Cos7
cells, constitutive over-expression of functional OPA1 could
trigger an overwhelming fission response by increasing
mitochondrial fusion.
Electron microscopic analysis showed that the fragmented
mitochondria from Mgm1p- or OPA1-depleted cells have an
altered internal structure [24,26,31]. Disorganized cristae with
irregular shapes and volumes, some of which showed enlarged
mitochondrial junctions, were often observed, together with
reticular elongated cristae running parallel to the longitudinal
axis of the mitochondria and occasionally forming stacks. Such
alterations provide evidence that dynamin, the great part of
which is located inside and not at the rims of the mitochondria[18,22,26,31], has a major function in structuring the
membranes of the cristae. However, dnm1 inactivation reverses
the changes seen in the organization of the cristae in mgm1-
deleted yeast, indicating that the role of Mgm1p in the structural
organization of the cristae may be an indirect effect of its
function in mitochondrial fusion [24].
Interestingly, some of the defects induced in the cristae by
loss of OPA1 are reminiscent of those occurring in the
mitochondria of apoptotic cells. Loss of the conserved
mitochondrial dynamin leads to cell death both in yeast and
in mammalian cells [11,25,31]. This cell death has been
attributed to the loss of mtDNA in the petite negative msp1+-
deleted fission yeast [25], while an mgm1 null mutant that lacks
respiratory function can still grow by fermentation on glucose
medium [10]. In mammalian cells, downregulation of OPA1
gives rise to an extreme sensitivity to exogenous proapoptotic
stimuli and an increase in the rate of spontaneous apoptosis, and
facilitates the release of cytochrome c from the mitochondria
both in vivo and in vitro [31,35,42].
Much data have now been accumulated with regard to OPA1
and its yeast counterparts, but the function of this protein
remains unclear (Fig. 2). Is OPA1 a global regulator of
mitochondrial dynamics or does it function primarily at the
level of the IM and/or the cristae? Is OPA1 strictly involved in
fusion and can the suggested effects on mitochondrial
fragmentation [26] of this member of a pro-fission protein
family be definitively ruled out? Does OPA1 have a direct role
in apoptosis and what are the underlying molecular mechan-
isms? Answering these questions will be complicated since
these processes are very intricate, and since numerous forms of
this dynamin, each of which may have specific localizations and
functions, are present in the cell. This later point is well
exemplified in yeast, where both the long form of Mgm1p,
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presumably involved in mtDNA maintenance, are essential
[17,30]. Furthermore, we have recently shown that differently
spliced OPA1 variants have distinct roles in mitochondrial
dynamics and apoptosis (unpublished data). Since mutations in
OPA1 are associated with autosomal dominant optic atrophy
(ADOA) [7,8], a cause of inherited blindness, a better
understanding of the functions of this dynamin is crucial to
gain further insight into the pathological processes associated
with this disease.
2.2. ADOA
Autosomal dominant optic atrophy (MIM #165500) is the
most common form of inherited optic neuropathy, with a
frequency of 1:12 000 to 1:50 000 [43,44]. This disease is
characterized by an insidious onset of visual impairment in early
childhood with moderate to severe loss of visual acuity,
temporal optic disc pallor, abnormalities of color vision and
caecocentral visual field scotoma [45–47] (Fig. 3). ADOA
shows variable expression, both between and within families,
ranging from an asymptomatic state to a legal blindness [47].
Electrophysiological and histopathological studies have sug-
gested that the underlying defect is retinal ganglion cell (RGC)
degeneration leading to atrophy of the optic nerve [45,48], as
observed in Leber's hereditary optic neuropathy (LHON), a
maternally transmitted disease caused by mitochondrial DNA
mutations [49].
Until now four gene loci have been designated for ADOA,
namely OPA1 (3q28–29), OPA3 (19q13.2–13.3), OPA4
(18q12.2–12.3) and OPA5 (22q12.1–q13) [50–53]. Among
these, the most common is OPA1, which was found by us and
others to be attributable to mutations in the OPA1 gene [7,8].
Ninety-six OPA1 gene mutations, mainly family-specific, have
been described so far [54]. The OPA1 mutations, of which 66,
29 and 5% are substitutions, deletions and insertions respec-
tively, are spread throughout the coding sequence of the gene,
but most are localized in the GTPase domain and in the 3′ end of
the coding region, whereas the 5′ region is little affected (Fig.
4). No obvious correlation between genotype and phenotype
could be detected [55–57], suggesting a role for other genetic or
environmental modifying factors. One deletion of the entire
OPA1 gene has been identified, strongly suggesting that the
mechanism underlying type 1-ADOA is haploinsufficiency
[58]. However, evaluation of the mutation spectrum suggests
more than one pathogenetic mechanism for the disease. Some
mutations may be semi-dominant, because one compound
heterozygote patient has been reported to have more severe
symptoms than his simple-heterozygote parents [57].
3. Can studies of Mgm1p/Msp1p/OPA1 help us to
understand type 1-ADOA?
3.1. Is haploinsufficiency the only cause of type 1-ADOA?
Two of the numerous different OPA1 mutations, one
corresponding to a deletion of the entire gene and the othervirtually the entire ORF (Trp2Stop), provide evidence that
haploinsufficiency is the cause of the disease [57,58].
Accordingly, almost 50% of the OPA1 mutations cause
premature truncations of OPA1 and nearly 40% are located
within the GTPase domain, possibly leading to the loss of
function of this dynamin. Nevertheless, we and others have
demonstrated that expression of GTPase mutants of Mgm1p
and Msp1p in yeasts (and OPA1 in MEFs) containing a wild
type allele of the appropriate dynamin induces mitochondrial
fragmentation [23,25,27,34] by a dominant negative effect. A
dominant negative mechanism is well documented for dyna-
mins with deficient GTPase activity [59,60]. This is related to
the ability of the mutated dynamin to form oligomers with the
wild type protein and thus to interfere with its GTPase activity.
Our preliminary results from an examination of the mitochon-
drial morphology in primary skin fibroblasts from patients
bearing a missense substitution in the GTPase domain of OPA1
indicate that a dominant negative effect may be involved in the
pathogenesis of type 1-ADOA. In cells from this patient, the
mitochondria appeared to be considerably more fragmented
than in fibroblasts from control individuals (our unpublished
data). Thus, the integration of GTPase mutated OPA1 into
oligomers with wild type OPA1 may decrease the GTPase
activity of the dynamin and thus the fusion competency of the
mitochondria. GTPase activity has indeed been shown to be
necessary for the function of Mgm1p/OPA1 in mitochondrial
fusion [23,24,26,34]. However, while oligomerization of
Mgm1p has been deduced using a genetic approach [23], no
data concerning the ability of OPA1 to oligomerize, and the
effect of oligomerization on its GTPase activity are available.
However, when taken together, the available results fit with both
the hypotheses that have been proposed as the pathophysiolog-
ical processes underlying dominantly inherited diseases.
Among the 96 OPA1 mutations identified, those occurring in
the GTPase domain would exert a dominant negative effect,
while the C-terminal truncations, by removing the potential
GED domain and thus abolishing the oligomerization-stimu-
lated activity of the dynamin, would cause haploinsufficiency. It
is of importance to clarify this point for future therapeutic
implications. Further investigations of the effects of OPA1
mutations on cells from type 1-ADOA patients, as well as a
biochemical characterization of wild type and pathogenic alleles
of OPA1 will be highly informative.
3.2. Is type 1-ADOA really tissue specific?
Even though it is not the only reported case, the tissue
specificity of type 1-ADOA is surprising for a disease for which
the genetic origin is a nuclear gene encoding a ubiquitously
expressed mitochondrial protein. While most abundant in the
retina, the OPA1 mRNA is widely distributed in mammalian
tissues [7,8,57]. OPA1 protein is also present in several tissues
[19,61], and it is not exclusively localized to the RGC since
OPA1 immuno-labelling was detected in the ganglion cell layer
as well as in the outer and inner plexiform layers and in the inner
nuclear layer in adult retinal tissues from mammals [61–64],
although discrepancies still persist on the cell types involved.
Fig. 3. Ophthalmologic diagnosis of ADOA. Results of an ADOA patient bearing an OPA1 mutation (B, D, F) are compared with those of a normal individual (A, C,
E). (A–B) Eye fundus photographs showing that the patient’s optic nerve disc is pale and that pallor predominates in the temporal side. (C–D) Color vision was tested
using the 15-hue Farnsworth's panel. The circling line indicates that the normal individual was able to harmoniously classify the 15 hues while the patient made a
disorganized classification with a confusion in the blue-yellow axis (tritanopia). (E–F) Dynamic perimetry using a Goldman apparatus to test the visual field. In the
normal individual, the blind spot is present as a small hatched area while in the patient it extends to the central visual field to form a centrocaecal scotoma (hatched
area). Three lines of equal retinal sensitivity (isotopers) are represented.
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nerve is somewhat controversial, since OPA1 was not detected
in the rat optic nerve [62], though it is highly expressed in the
mouse optic nerve axons [63]. Surprisingly, OPA1 is expressed
in the myelinated regions of the human optic nerve, which show
a decreased number of mitochondria as compared to the somata
of the RGC, where biogenesis of mitochondria occurs, and tothe fiber layer containing unmyelinated axons before the lamina
cribosa [61].
Since OPA1 is widely expressed in many tissues the reason
that RGC are primarily affected by OPA1 mutations remains
unknown. Nevertheless, the somewhat specific distribution of
the mRNA and protein variants of OPA1 [19,28] may suggest
the involvement of a specific form of this dynamin in the
Fig. 4. Mutation spectrum of OPA1. Distribution of the 96 mutations of OPA1 according to their type (A), domain (B) and location (C). In B, only mutations affecting
exons are considered and domains correspond to those described in Fig. 1. In C, spaces between two consecutive exons correspond to introns and colored bars under
exons indicate their belonging to OPA1 domains.
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reports of sensorineural hearing loss associated with dominant
optic atrophy caused by the R445H mutation in OPA1 in several
unrelated families [65–68] indicate that the RGC are not the
only cell types affected in type 1-ADOA. The widespread
distribution of OPA1 in the sensory and neural cochlear cells of
the guinea pig supports the hypothesis of the involvement of the
auditory nerve in OPA1 dysfunction. Fibroblasts from patients
bearing the R445H allele were shown to contain highly
fragmented mitochondria [68]. It is not clear why the R445H
mutation, located within the GTPase domain, cause a broader
spectrum of disease whereas other mutations identified to date
are associated with optic atrophy alone. Comparative biochem-
ical and biological characterizations of this particular allele
should help us to understand the molecular basis of this ADOA
“plus” syndrome, as will careful examination of auditory
performance in type 1-ADOA patients and screening for OPA1
mutations in patients suffering sensorineural hearing loss.
Furthermore, clinical studies are currently being undertaken to
determine if type 1-ADOA patients show muscular, cardiac and
neuronal extra-ocular deficits that could signal a more
generalized mitochondrial dysfunction (C. Hamel and G.
Lenaers, personal communication).
3.3. Does RGC degeneration occur via an apoptotic process?
There are multiple parallels that link the two major
neurodegenerative disorders of the RGC, type 1-ADOA and
LHON. A set of elegant experiments investigating LHON
cybrid death pathways in glucose free/galactose medium
(which reduces the rate of glycolytic flux, thereby forcing
cells to utilize oxidative metabolism) has shown that the threecommon LHON mutations which affect complex I (the ND1,
ND4, and ND6 subunits) cause an increased sensitivity to
caspase-independent apoptotic cell death [69–71]. Consider-
ing that we and others have demonstrated that downregulation
of OPA1 induces spontaneous apoptotic cell death and
sensitizes cells to exogenous apoptotic stimuli [31,35], it is
tempting to propose that apoptosis may represent the
pathophysiological process leading to the degeneration of
the RGC in type 1-ADOA. Preliminary results that we have
obtained using skin fibroblasts from patients bearing patho-
genic GTPase and GED OPA1 mutations support this
hypothesis. These cells show an increased sensitivity to
staurosporine-induced cell death when compared to fibroblasts
from controls individuals (our unpublished data).
Thus, the mitochondrial dysfunction common to both LHON
and type 1-ADOA seems to be a predisposition of the neuronal
cells to apoptotic death. In LHON this feature has been
proposed to be mediated by a deficient complex I, which
impairs the efficiency of the respiratory chain, thereby lowering
ATP synthesis and increasing ROS production [49]. A similar
mechanism could occur in type 1-ADOA, since drops in the
mitochondrial membrane potential and cellular respiration
occur in cells where OPA1 expression has been downregulated
[31,41]. Interestingly, recent results obtained from primary
cultures from type 1-ADOA patients [68] fit with the in vivo
data obtained using 31P magnetic resonance spectroscopy that
demonstrate defective ATP synthesis in skeletal muscle from
these patients [72]. Nevertheless, in type 1-ADOA the primary
defect would be attributed to the role of OPA1 in mitochondrial
dynamics and/or the structural organization of the cristae.
Several studies have indicated that mitochondrial morphol-
ogy changes during apoptosis induced by different agents such
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round organelles [73,74]. Furthermore, inhibition of the
mitochondrial fission machinery and upregulation of mitochon-
drial fusion reduce cell death, suggesting a role for mitochon-
drial fragmentation in apoptosis [31,35,74–76]. The underlying
effect of OPA1 on apoptosis could thus be its pro-fusion
activity. RNAi experiments have shown that loss of OPA1
induces spontaneous apoptotic death or an increase in
sensitivity to exogenous pro-apoptotic stimuli, together with
fragmentation of the mitochondrial network [31,34,35,42].
Taken together these results suggest that loss of fusion activity
leaves the fission forces unopposed resulting in excessive
mitochondrial fission and cell death. On the other hand, we and
others have shown that loss of OPA1 induces a drastic change in
the structure of the cristae [26,31,42]. It has been proposed that
only 15% of the total cytochrome c is available in the inter-
membrane space, with the remainder being sequestered in the
narrow junctions within the cristae [77]. Downregulation of
OPA1 has been shown to induce spontaneous cytochrome c
release, and to accelerate the release of cytochrome c induced by
apoptotic stimuli [31,42]. Hence, downregulation of OPA1 has
been proposed to account for the rapid and complete
cytochrome c release observed during apoptosis. Thus, the
reorganization of the cristae mediated by the loss of OPA1 could
represent the mechanism underlying the effect of this dynamin
on apoptosis. Recent experiments showing that OPA1 is co-
released with cytochrome c from the mitochondria before their
fragmentation support this hypothesis [42]. On the contrary, the
finding that the morphology of the cristae is restored to normal
upon dnm1 inactivation in mgm1-deleted yeast contradict this
hypothesis [24]. The recent discovery that OPA1 needs Mfn1 to
control mitochondrial dynamics [34] may help us to discrim-
inate between these two models. Nevertheless, interesting data
could reconcile both hypotheses since they lead to the
proposition that, through DRP1 (the dnm1 orthologue)-
mediated signaling, fission is coupled to the remodeling of
the cristae [78]. Further analyses are required to support these
different hypotheses, and promise exciting breakthroughs in the
near future both with regard to the pathogenesis of type 1-
ADOA, and with regard to mitochondrial dynamics and their
relationship to apoptosis.
4. Discussion
In 1988 Wallace identified the first substitution in the
mtDNA causing a genetic disorder which was originally
described by Leber in 1871, thereby beginning the list of
optic neuropathies linked to mitochondrial dysfunctions [79–
81]. The discovery, in the year 2000, that the genetic cause of
the most common group of ADOA is OPA1, a nuclear gene
encoding a mitochondrial dynamin [7,8], together with the
finding that OPA3, the third gene identified as involved in
primary optic atrophies, encodes an IM protein [52,82],
definitively demonstrates that the optic nerve is highly
dependent on mitochondrial functions. This raises the interest-
ing possibility that the yet unidentified causative genes for
ADOA (OPA4, MIM605293 and OPA5, [53]), as well as for therare isolated autosomal recessive optic atrophies (ROA,
MIM258500), encode mitochondrial proteins. Mitochondrial
dysfunctions may be suspected not only in the primary optic
atrophies, in which degeneration of the optic nerve is the main
and often the only clinical feature of the disease, but also in
primary optic atrophies accompanied by secondary defects,
often neurological. This is well exemplified in the Costeff
syndrome (MIM258501), a neuro-opthalmologic disease
caused by recessive mutations in OPA3 [83]. Furthermore,
secondary optic atrophy is also frequently reported as one of the
clinical features of multisystem disorders associated with
mtDNA mutations including MELAS (MIM5400000), LS
(MIM256000), KSS (MIM 530000), NARP (MIM 551500),
MERRF (MIM545000). In addition, certain acquired dietary
(vitamin B12 or folic acid deficiencies) or toxic (ethambutol,
chloramphenicol uses) optic neuropathies have also been
reported to be associated with mitochondrial dysfunctions.
What makes the optic nerve so vulnerable to mitochon-
drial dysfunction? One common hypothesis for why neurons
are so sensitive to mitochondrial dysfunction is that they have
a high demand for energy in regions that may be at a
considerable distance from the cell body, where the
biogenesis of the mitochondria occurs. Bioenergetic defects
may be deleterious for the conduction of action potentials, as
well as for mitochondrial transport, and may thus result in
nonfunctional synapses, axonal degeneration and ultimately
cell death. Due to the high energy demand required for the
conduction of electrical impulses through the anterior
unmyelinated portion of the axons, and the long course of
the axons, the RGC may be a bioenergetically weak element
of the central nervous system. Since OPA1 expression is
ubiquitous, and since it was recently proposed that neither the
pattern nor the abundance of OPA1 mRNA and protein
variants are specific to RGC [64], a plausible hypothesis as
to why these neurons may be more vulnerable to OPA1
inactivation could be a particular susceptibility to mitochon-
drial membrane disorders inducing mitochondrial dysfunction
or mislocalization. While the former point is in agreement
with reports that describe altered mitochondrial ATP synthesis
and respiration in OPA1-inactivated cells [41,68,72], the latter
may relate to the particular distribution of the mitochondria
in RGC. These show an accumulation of mitochondria in the
cell bodies and in the intraretinal unmyelinated axons, where
they accumulate in the varicosities, and a relative paucity of
mitochondria in the myelinated parts of axons [84–86].
Furthermore, the effect of mitochondrial dynamics on the
correct intracellular distribution of the mitochondria and its
influence on neuronal plasticity and function was recently
highlighted by inactivation of DRP1 in live hippocampal
neurons [67]. Link between axonal transport of mitochondria
[87] and mitochondrial dynamics was also enlighted by a
recent study showing that Drosophila mutants lacking DRP1
failed to populate the distal axon with mitochondria, affecting
the mobilization of the synaptic vesicle reserve pool [88,89].
Considering the sum of these data, it is not surprising that
mutations in the pro-fusion protein Mfn2 cause a peripheral
neuropathy [9].
507A. Olichon et al. / Biochimica et Biophysica Acta 1763 (2006) 500–509A better understanding of the role of mitochondrial dynamics
in mitochondrial and cellular function is essential to evaluate the
physiological and physiopathological impact of these processes.
Finally, it can be predicted that identification of other molecular
constituents of the fission and fusion machineries would be
helpful in identification of genes responsible for optic atrophy
and more generally for neurodegenerative disorders.
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